T h e re is a greater relationship between merosin and the former proteins; among MP-CMD patients, no remarkable immunohistochemical/phenotypical correlations were found, although the reduced expre ssion of β-DG had showed statistically significant correlation with severe phenotype and marked fibro s i s on muscular biopsy.
Congenital muscular dystrophy (CMD) re p res e n t s a heterogeneous group of diseases characterized b y early onset of hypotonia and weakness (neonatal or during the first year of life), and non specific m u scular dystrophic pattern 1 , 2 . The disorder can be limited to the muscles or associated with the central n e rvous system (CNS) and/or eye abnorm a l i t i e s . D i ff e rent specific phenotypes have been described, many of them defined on a molecular basis 3 . The most common form, CMD1A, accounting for about 40% of the cases, is due to mutations in LAMA2 gene (6 q2) , which codes for α2-laminin2 ( m e ro s i n ) 1 -4 . Other defined although rarer forms are: Ullrich CMD (COL6A1, COL6A2, COL6A3 genes, 21q22, 2q 37) with α-1, α-2 or α-3 collagen VI deficiency 4 -5 ; CMD with rigid spine (SPT1 gene, 1p35) with selen o p rotein N 1 deficiency 6 ; CMD1C (FKRP gene, 1 9 q 1 ) with fukutin related protein deficiency 7 ; CMD1D (LARGE gene, 22q12) with acetylglucosaminyltransferase-like protein deficiency 8 ; Fukuyama CMD (FCMD gene, 9q31) with fukutin deficiency 9 ; muscle-eye-brain (MEB) disease (POMGnT1 gene, 1p33) with O-mannose β-1 , 2 -N -a c e t y l g l u c o s a m i n y l t r a n s f erase deficiency 1 0 and Walker Wa r b u rg (WW) CMD (POMT1 gene, 9q34) with deficiency of O-mannos y l t r a n s f e r a s e 1 1 . Cases with no identified genetic defects belong to the merosin-positive (MP) CMD s u b g roup. In 1998, an early onset muscular dystrophy with diaphragmatic involvement, early re s p i r at o ry failure, calf or generalized muscle hypert rop h y and secondary alpha2 laminin deficiency was assigned to 1q42 and named CMD 1B 1 2 but a specific gene or protein has not been defined yet.
The above classification of CMD forms was in p a rt facilitated by the recent knowledge about d efined or putative glycosiltransferases that interf e re with the glycosilation of dystroglycan (DG) f ro m the muscular membrane. The muscle-eye-brain forms, i.e. Fukuyama CMD, MEB disease and WW s y n d rome, and other forms of CMD with norm a l m e rosin or partial deficiency (CMD1B, 1C and 1D) have been associated with glycosilation defects of a -d y s t ro g l i c a n 3 , 1 3 , 1 4 which currently re p resent a b road field for re s e a rchers. In spite of the continuous advances, within the MP-CMD subgroup there a re some apparently specific clinical phenotypes t h a t could re p resent new genetic and biochemical subtypes not yet identified.
Our objective was to analyse the expression of the components of the dystro p h i n -g l y c o p roteins a ssociated complex (DGA) in muscle biopsy of pat i e n t s with diff e rent forms of CMD, in an attempt of correlating such findings with clinical and histopathologic data.
METHOD
F rom January 1990 to June 2002 we have followed 5 9 patients aged 0 to 15 years with a diagnosis of CMD based on clinical, i.e.early onset of muscle weakness and h ypotonia, as well as a histopathological criteria that define dystrophic pattern on muscle biopsy, i.e. fiber size v ar i a b i l i t y, endo/perimysial fibrosis and fatty infiltration ( Tables 1 and 2). All patients have been examined periodically by one of us.
Muscle samples were obtained from the biceps brachial, rapidly frozen in liquid nitrogen and processed by routine histological techniques. The intensity or amount of the above histopathological changes were graded as follows: -absent; + mild; ++ moderate; +++ marked; ++-++ severe and widespread.
The immunohistochemical study was perf o rmed on muscle sections by means of immunofluorescency15 or i m m u n o p e roxidase methods, using the following primary antibodies to: merosin, 80 kDa, (monoclonal, Life Technologies), diluted 1/1000; laminin α2 chain (mero s i n ) , 300 kDa (Mer 3/22B2, Novocastra), diluted 1/800; dystrophin, carboxy terminus (Novocastra, Dy8/6C5), diluted 1/1000; α-s a rcoglycan (Novocastra, Ad1/20A6), diluted 1/100-200; β-s a rcoglycan (Novocastra, bSarc/5B1), diluted 1/100-200; γ-s a rcoglycan (Novocastra, 35DAG/21B5), diluted 1/100-200; δ-s a rcoglycan (Novocastra, d S a rc 3 / 1 2 C I ) , diluted 1/100-200; β-dystroglycan (Novocastra, g43DA-G1/8D5), diluted 1/100-200; dysferlin (Novocastra), diluted 1/20; collagen type VI (Development studies Hybridoma Bank), diluted 1/100 e α-d y s t roglycan (kindly given b y D r. Stephan Kroger), diluted 1/2000. FITC-conjugated a n t imouse was used as a secondary antibody. The immunoreactivity evaluation, perf o rmed by two of the authors, followed Hayashi methodology 1 6 : negative (-); minimal (±), positive or normal (P) and decreased or irre g u l a r (weak).
The following clinical features were evaluated: age at onset, maximal motor ability, serum creatine kinase (CK) level, mental status and brain neuroimaging changes (Tables 1 and 2) .
A statistical analysis was perf o rmed utilizing the Pearson chi-squared test17 for testing the possible association or independence between each component of the clinical, histopathological and immunohistochemic a l variables categories. All results were considered as mean ± standard deviation and expressed as a level of significance of 0.05 (α = 5%).
RESULTS
After clinical evaluation, immunohistochemical test for merosin and brain neuroimaging pro c ed u res, 32 patients were classified as MP, 23 as MD, one as Ullrich CMD and three as WW syndro m e (Tables 1 and 2) .
With re g a rd to 32 MP patients (21 male, 11 female), 12 were not symptomatic at birth and 5 nev-er acquired independent walking (Table 1) . One child presented marked cervical weakness. Thre e had minor mental re t a rdation (MR), one modera t e MR and two, among 22 who were submitted to magnetic resonance imaging (MRI), had focal and nonspecific white matter abnormalities. Other a b n o rmal findings on MRI were brain cortical atrophy in two patients and cerebellar atrophy in one. CK was normal in 9 patients, 2 to 5 times up fro m the normal in 13, up to 5 times the normal in 7 a n d not available in three patients. Two children had cataracts and one had Type 1 diabetes mellitus.
All the 23 MD patients (11 male, 12 female) manifested symptoms at birth and only three acquire d independent walking (that was after lost in two). One of them re c o v e red independent walking for a period while receiving deflazacort. All patients had n o rmal intelligence and presented white matter a b n o rmalities on brain MRI. CK was normal in one patient, increased until 5 times in 10, above 5 times in 11 patients, and not available in one ( Table 2 ). The only patient with Ullrich phenotype, confirmed as UCMD by molecular analysis 1 8 had symptoms at birth and never acquired walking. He had normal intelligence and normal CK level.
All the 3 children with WW syndrome (1 male, 2 female) manifested symptoms at birth, were neve r able to walk, presented severe MR and neuronal m igration defects (lissencephaly) on brain MRI. The C K level was normal in one patient and increased above 10 times in the remaining two.
Eight patients (Cases 12, 32, 34, 35, 36, 39, 40 a n d 55) died due to re s p i r a t o ry interc u rrences. Three o f them (Cases 34, 35, and 36) were diagnosed as WW s y n d rome, three (Cases 39, 40, and 55) had MD-CMD and among the two MP-CMD patients who died, one had a severe MR (Case 12) and the other had Type 1 diabetes mellitus (Case 32).
Immunohistochemical data (Table 3) D y s t rophin and dysferlin expression were normal in all patients. Among the 23 MD patients, the deficiency was partial in 9 (detected with the antibody 80 Kda in two, 300 Kda in 5, and both in two).
C o n c e rning α-s a rcoglycan (SG) and γ-SG expre ssion, each one was reduced in 5 (15.6%) of the 32 MP patients, as well as in 18 (78.2%) and 8 (34.7%) of the 23 MD patients, respectively. The δ-SG and β-SG expression was evaluated in 31 MP and in 23 MD patients and resulted normal in all, except in one MP patient, who presented a reduced expre ssion of β-SG.
The β-DG reaction resulted weak in 7 patients (22.5%) among 31 with MP and in 6 (26%) among 23 with MD. The a-DG reaction, evaluated in 22 M D and in 22 MP patients, resulted weak in 11 (50%) and in two (10%) patients, re s p e c t i v e l y. Add i t i o na l l y, in two patients with WW a weak strain was o bserved in each one of β-SG and γ-SG, respectively.
The reduction of the expression of a-SG and α-DG showed statistically significant corre l a t i o n ( Table 4) with the diagnosis of MD-CMD (p = 0,00 e p = 0,003, respectively) Among MP-CMD patients, the reduced expre ssion of the β-DG had statistically significant corre l ation with both, a severe phenotype (walking abili- 
300 kd 1 P P NA P P P P P P P 2 P P NA P P P P P P P 3 P P P P P P P P NA P 4 P P P P P P P P NA P 5 P P P P P P P P P P 6 P P P P P P P P P P 7 P P NA P P P P P NA P 8 P P NA P P P P P P P 9 P P NA P P P P P P P 10 P P NA P P P P P NA P 11 P P NA P P NA P NA NA NA 12 P P P P W P W P P W 13 P P NA P P P P P P P 14 P P NA P P P W P NA P 15 P P NA P W P P P P P 16 P P NA P P P P P P P 17 P P P P P P W P P P 18 P P P P P P P P P P 19 P P P P P P P P P W 20 P P P P W W P P P W 21 P P NA P W P W P P P 22 P P P P P P P P P P 23 P P P P P P P P P W 24 P P P P P P P P NA P 25 P P NA P P P P P W P 26 P P P P P P P P NA P 27 P P P P P P P P NA P 28 P P P P P P P P NA W 29 P P P P P P P P P P 30 P P P P P P P P P P 31 P P NA P W P W P P W 32 P P NA P P P P P W W 33 P P -P P P P P P P 34 P P P P P W P P P P 35 P P P P W P P P P P 36 P P P P P P P P P P 37 -/+ -/+ P W P P P NA P P 38 DISCUSSION R e g a rding the MD patients, our aim was to evaluate the influence of the primary deficiency of merosin on the expression of the main proteins of the DGA complex, comparing their expression with that observed in MP patients. In the MP patients o u r intention was to select possible clinical particularities according to the protein expression. Merosin -In 9 patients among 23 merosin deficiency was partial. All manifested the abnorm a l white matter on brain neuroimaging and clinical s everity that characterize the MD patients with total absence of mero s i n 1 9 -2 1 . Although patients with CMD due to mutations in other genes, part i c u l a rly those related with abnormal glycosilation of α-d y s t roglycan can present a secondary partially deficient merosin 3, 13, 14 , until the moment the association between widespread white matter changes a n d p a rtial merosin deficiency has only been described in patients with mutations in the LAMA2 gene. In DMC1C (FKRPgene) 7 , the partial deficiency of merosin is secondary to the marked deficiency of α-d y s t roglycan and is not associated with brain white matter changes. In the muscle-eye-brain forms of CMD, like Fukuyama and MEB, a secondary defic i e ncy of merosin may occur; however, such forms are easily distinguished from classic MD-CMD with partial deficiency by their characteristics ocular and brain changes [1] [2] [3] .
The adequate identification of the partial deficiency of merosin depends on the use of diff e re n t antibodies that recognize diff e rent fragments of the pro t e i n 2 2 , 2 3 . The most useful antibodies are those reacting to the merosin fragments of 80 and 300 k D a 2 3 . In two of our 9 patients with partial deficienc y, we defined that the deficiency was partial only after the utilization of the antibody against 300kDa, as with the antibody against 80 kDa, the mero s i n seemed totally absent. This result, indicating the better sensibility of the antibody against 300 kDa, is in a g reement with other studies 2 4 , 2 5 . The possibility that not yet identified subtypes of CMD may also pre sent secondary partial deficiency of merosin re i nf o rces the need of a careful investigation of mero s i n status in the muscular biopsy of CMD patients.
Even presenting a total deficiency of merosin, two CMD patients (Cases 53 and 54) acquired independent walking, and the youngest of them still maintains it. This finding is not re p o rted in the casuistics about CMD patients with total absence of m e ro s i n 2 0 , 2 6 . One of these three totally MD patients (Case 54) deserves a special comment, as her ability for walking independently, that had been lost a t 4 years of age, was re c o v e red and maintained for two more years under steroid therapy. In conclus i o n in our MD patients, the ability to walk independently was not fully related with the partial or total m e rosin deficiency and the degree of clinical severity was not related to any particular immunohistochemical finding.
D y s t rophin -
The expression of dystrophin in the patients' samples was normal in all, independently of the merosin status and of the degree of histopathological dystrophic changes. Therefore, the severe clinical and muscular involvement obs e rved in CMD patients is apparently not due to an abnormal interaction between laminin and dyst rophin. However, it must be emphasized that we evaluated the dystrophin expression by using antibodies against the C-terminal domain only and n o t against the N-terminal or the central region domains, that could interf e re with the correct interp retation of the interaction between laminin and all the human dystrophin domains. In fact, Fard e a u et al. 1 9 , using antibodies against the central re g i o n and N-terminal dystrophin dominium, demonstrated that the primary merosin deficiency can induce a secondary dystrophin deficiency.
Sarcoglycan complex -The correct association among the α, β, γ, d and ε s a rcoglycans within the s a rcoglycan complex has been widely discussed and t h e re is not a perfect agreement among diff e re n t re s e a rc h e r s 2 7 -2 9 . More studies about the assembly and interactions of sarc o g l y c a n / s a rcospan complex will contribute to better clarify the muscle function. In our CMD patients, the normal β and δ-s a rc o g l ycan expression agrees with the literature 3 0 . A statistically significant decrease of α-s a rcoglycan expre ssion was observed in our MD patients (Table 4) , probably indicating a stronger interaction between t h a t p rotein and merosin, through their link with β-d y st roglycan. In any case, the greater dystrophic changes seen in MD patients could also interf e re with the a-sarcoglycan expression. We also found, a dec rease of γ-s a rcoglycan expression, mainly in the MD patients (34.7%), but without statistical significance (Table 4) . This finding could also suggest a closer connection between γ-s a rcoglycan and merosin; however, both MD and MP patients, who presented severe dystrophic pattern, also presented a g reat, but not clinically significant reduction of γ-s a rcoglycan (Table 4 ). There f o re, future studies about the relation between sarcoglycan expre s s i o n and dystrophic pattern would be necessary.
In relation to WW, the sarcoglycans and merosin expression is variable. In general there is a s e c o n d a ry deficiency in the expression of mero s i n and α-s a rc o g l y c a n 3 1 . In three patients we observ e d n o rmal merosin and a reduction of β-SG in one a n d of γ-SG in another patient.
D y s t roglycan complex -The dystroglycan gene codes for a proteic precursor that processed by a p rotease results in α e b-DG 3 2 , 3 3 . The β-DG has a t r a n s membrane domain and is directly connected to the cystein portion of the dystrophin by the C-term i n a l 3 2 . The α and β-DG interact directly in the extracellular matrix.
Although a normal expression of β-DG in both MD and MP patients has been re p o rt e d 3 4 , as the β-DG interacts with the merosin through the α-D G connection, it could be expected that in the prim a ry absence of the merosin, the β-DG could also be reduced. In fact, we observed such reduction i n some patients, but the percent of MP and MD patients presenting reduction in the β-DG staining w a s almost the same (22.5% and 26%, re s p e c t i v e l y ) . Besides, in the MP patients the β-DG reduction was statistically correlated to the intensity of the dystrophic pattern (Table 6 ). This seems to suggest that the partial reduction of the β-DG in CMD patients is probably more related to the dystrophic pattern and other correlated factors than to the absence o f m e rosin. Finally, the possibility that mutations in genes not yet defined encoding other proteins c o u l d also justify this secondary β-DG reduction should be stressed.
As demonstrated in other studies, the α-DG exp ression can be variable in MD patients 3 0 . In our c ases, the α-DG was reduced in 50% of the MD patients and in only 10% of the MP patients. This diff e rence was statistically significant (Table 4 ) and w a s dependent on the closer relation between mero s i n and α-DG, already emphasized by others 7, 30, 35 .
A b n o rmalities in the α-DG glicosilation have been considered important in the pathogenesis of many forms of CMD: Fukuyama, MEB, WW, 1C and 1 D 3, 7, 8, 13, 30, [35] [36] [37] . In most of these cases a secondary d eficiency in merosin has been detected. We only found two MP patients with reduced expression of α-DG and their clinical phenotype did not correspond to the clinical description re p o rted in the new CMD forms with α-DG glicosilation defects 7 , 8 . One of these patients has a marked involvement of the cervical musculature (Case 25) and the othe r (Case 32) presented focal changes in brain white matter and Type 1 diabetes mellitus. Both had normal expression of the merosin. A phenotype very s imilar to that observed in Case 32, except by the lack of Type 1 diabetes mellitus, was found in Case 3 1 ; however this patient had normal α-DG expre s s i o n . It is important to emphasize that those cases with brain white matter changes, like our Cases 31 and 32, would need the study of the LAMA2 gene for ruling out any mutation that according to Tezak e t a l . 3 8 could lead to retention of large fragments of m e rosin. However, in the routine attendance the homogeneously clinical severity and the wides p read brain white matter changes typical of CMD-1A, in addition to the low availability of molecular studies of the LAMA2 gene, lead to the diagnosis of MD-CMD.
The phenotype of our WW patients was markedly homogeneous and similar to that reported in the literature 3 9 . A neonatal severe involvement of muscles and CNS (type II lysencephaly) leading t o death in the first two years of life was the rule. Recently mutations in the O-mannosyltransferase 1 have been identified 4 0 , suggesting that the O-manose glicosilation would be implicated in the neuronal migration process at least in one part of the WW patients. Both α-DG and merosin expre s s i o n , w e re found to be reduced in the CMD with glycosilation defects 7 , 3 5 , 4 1 ; however we did not find the f o rmer abnormalities, perhaps because not all the WW cases are associated to O-mannosyltransferase gene (POMT1) 40 .
Collagen VI -We tested the collagen VI expre ssion in 7 MP patients with marked distal joints hyperlaxity and variable degrees of muscular involvement. In two, the collagen expression was absent and one of them was later diagnosed as Bethlem myopathy and taken off from the present series 1 8 . The other (Case 33) was the only patient in our ca-suistics who was diagnosed as Ullrich CMD by molecular analysis 1 8 . The Ullrich phenotype, characterized by distal joints hyperlaxity associated with p roximal joints contractures is clinically and genetically hetero g e n e o u s 4 2 , 4 3 and corresponds to Ullrich CMD, i.e. associated to mutations in one of the t h re e collagen VI genes in about 40% of the patients 4 2 .
Closing remarks -Unlike MD patients who pre sent homogeneous clinical severity and neuro i m a ging changes, our MP patients had a variable motor i m p a i rment and in 6 of them we found CNS involvement, which we had in part already discussed in a previous work 4 4 . The CNS involvement was m anifested by MR (Cases 6, 11, 12, 24), brain and cerebellar atrophy (Cases 4 and 12, respectively), as w e l l as by focal and non specific changes of brain white matter (Cases 12, 31, 32). As has already been s t re ssed, the finding of focal changes of the brain white matter in two MP patients (Cases 31, 32) not associated to other neurological abnormalities would suggest the need for molecular analysis of the LAMA2 gene for ruling out MD-CMD. However, the homogeneous and typical clinical/neuro i m a ging picture, as well as the use of two antibodies, against 80 and 300 kDa fragments of mero s i n , seems sufficient for defining the diagnosis of MD or MP-CMD. Two MP patients (Cases 6 and 24) had cataracts in addition to MR and this association had also been previously re p o rted by us 4 5 . Concerning the MP patient with Type I diabetes mellitus (Case 32, already deceased) it is difficult to define whether that association was fortuitous or genetically determined. There f o re, we did not find in the MP patients who manifested the above mentioned uncommon findings of CNS and/or ocular involvement, as well as of type I diabetes mellitus, any specific change in the expression of any of the p roteins from the DGA complex. Still within the MP-CMD subgroup, two patients had a rigid spine phenotype (Cases 14 and 23), and would need genetic confirmation to eventually be included in the subgroup of CMD with rigid spine linked to c h romosome 1p 6 . Although the majority of our MP patients present a less severe phenotype and maintain the capacity to walk, two our patients ( C ases 11 and 12) presented an intense motor and re spiratory impairment, similar to those observed in the MD group. In these patients, the immunohistochemical analysis of the proteins from the DGA complex did not detect any abnormality.
In conclusion, although our study did not characterize any remarkable clinical-immunohistochemical correlation, we consider that an immunohistochemical analysis as complete as possible, should be perf o rmed, for establishing the diff e rential d i a gnosis with other forms of children myopathies, w h i l e we await more accessible molecular methods. In addition, the analysis of the immunohistochemical expression of the proteins from muscle and extracellular matrix with a number of already available antibodies, is an easy pro c e d u re, that can contribute for a better understanding of the pathogenesis of the dystrophic muscle, as well as for selecting a particular molecular study.
